NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: American Heart Association's New Initiative for Aortic Stenosis Diagnosis and Clinical Trials
TL;DR
The American Heart Association's new initiative with Kardigan provides earlier access to innovative treatments, giving patients and providers an advantage in managing aortic stenosis.
The American Heart Association is expanding its Target: Aortic Stenosis program to connect patients with clinical trials through 40 hospitals and heart valve clinics.
This initiative helps people with aortic stenosis receive earlier diagnosis and treatment, creating healthier lives and advancing care for this serious heart condition.
Over 2,200 people with moderate aortic stenosis are already managed through this network, which now expands to include clinical trial opportunities.
Found this article helpful?
Share it with your network and spread the knowledge!
The American Heart Association has launched a new effort to boost clinical trial participation and speed diagnosis of aortic stenosis, connecting patients with moderate AS to research opportunities through a nationwide network of hospitals and heart valve clinics.
Aortic stenosis is a heart valve condition characterized by narrowing of the aortic valve opening, which restricts blood flow from the heart to the body. Untreated, it can lead to severe complications including heart failure and death.
This initiative is important because aortic stenosis is often underdiagnosed until the disease progresses, and it will help shape the future of care by identifying eligible participants for clinical trials and supporting clinical research.
The American Heart Association is leading this initiative, with Dr. Sreekanth Vemulapalli serving as the volunteer project clinical leader, and it is supported by Kardigan and leverages the established infrastructure of the Target: Aortic Stenosis™ program.
The initiative will engage at least 40 hospitals and their affiliated heart valve clinics to connect individuals with research opportunities, provide professional education and quality improvement tools to clinicians, and conduct a healthcare provider climate survey to explore barriers to trial enrollment.
This initiative is being implemented across the American Heart Association's nationwide network of hospitals and heart valve clinics throughout the United States.
The initiative will help patients gain earlier access to innovative care and treatment, promote emerging medical therapy alternatives, advance guideline-based care, and help more people receive diagnosis and treatment sooner.
More than 2,200 people with moderate aortic stenosis are already managed through the Association's existing Target: Aortic Stenosis™ quality improvement network.
Patients can visit the American Heart Association's website at https://www.heart.org/en/health-topics/heart-valve-problems-and-disease/heart-valve-problems-and-causes/aortic-stenosis to learn how to identify symptoms and understand risks.
Healthcare professionals can access the latest programs, resources, science and webinars at https://www.heart.org/en/professional/quality-improvement/target-aortic-stenosis/resources-for-healthcare-professionals.
Curated from NewMediaWire
